Opinion|Videos|May 20, 2025
The Use of PARP Inhibitors in Ovarian Cancer
Author(s)Kathleen Moore, MD, MS
PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers.
Advertisement
Episodes in this series
Video content is prompted by the following:
PARP Inhibitors in Ovarian Cancer Treatment
Key Themes:
- Biomarker-directed PARP inhibitor use in frontline treatment
- Current FDA approvals and indications
- Overall survival concerns in platinum-sensitive settings
Notable Insights:
- Current frontline approvals:
- Olaparib monotherapy maintenance for BRCA1/2 mutations after response to platinum
- Olaparib with bevacizumab for HRD-positive tumors
- Niraparib approved for all-comers whose tumors responded to chemotherapy
- Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency.
- The FDA restricted platinum-sensitive setting approvals to BRCA-positive patients only due to concerns about potential survival detriment in non-BRCA populations.
Dr Moore stated: “PARP inhibitors are the first truly targeted therapy to benefit patients with ovarian cancer...transformative in a biomarker selected way” and noted: “Best place to use them is in frontline...there is the chance we are curing more patients. We believe that.”
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.
Hepatitis reports after vaccination were more often serious in children, but the data lack dose counts and cannot show vaccine-specific risk.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves First Symptomatic Dermographism Treatment
3
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5